Phaseline

Companies › Ikaria Bioscience

Ikaria Bioscience: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RN3161–Phase 1Obesity &Amp; OverweightFeb 2027
RN5681–Phase 1High CholesterolFeb 2027
RN0361–Phase 1Hypertriglyceridemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06471543RN0361Phase 1HypertriglyceridemiaMetabolic and endocrineJun 2026
NCT07245771RN3161Phase 1Obesity &Amp; OverweightMetabolic and endocrineFeb 2027
NCT07347678RN5681Phase 1High CholesterolMetabolic and endocrineFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.